1201924-32-4

Basic information

• Product Name: 2-Pyridinecarboxylic acid, 6-chloro-3-methyl-
• Synonyms: 2-Pyridinecarboxylic acid, 6-chloro-3-methyl-;6-Chloro-3-methyl-pyridine-2-carboxylic acid
• CAS NO: 1201924-32-4
• Molecular Formula: C₇H₆ClNO₂
• Molecular Weight: 172
• Mol File: 1201924-32-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 333.7±37.0 °C(Predicted)
• Appearance: /
• Density: 1.390±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.93±0.32(Predicted)
• CAS DataBase Reference: 2-Pyridinecarboxylic acid, 6-chloro-3-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxylic acid, 6-chloro-3-methyl-(1201924-32-4)
• EPA Substance Registry System: 2-Pyridinecarboxylic acid, 6-chloro-3-methyl-(1201924-32-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1201924-32-4(Hazardous Substances Data)

Usage

Uses

6-Chloro-3-methylpyridine-2-carboxylic Acid is disubstituted pyridinecarboxylic acid used in the preparation of biologically active compounds such as inhibitors of Janus kinases and PDK1.

InChI:InChI=1S/C7H6ClNO2/c1-4-2-3-5(8)9-6(4)7(10)11/h2-3H,1H3,(H,10,11)

Upstream product

• 850864-54-9 ethyl 6-chloro-3-methyl-pyridine-2-carboxylate 
• 850864-53-8 ethyl 3-methyl-1-oxido-pyridin-1-ium-2-carboxylate 
• 4021-07-2 3-methyl-pyridine-2-carboxylic acid 
• 58997-10-7 ethyl 3-methylpyridine-2-carboxylate 
• 878207-91-1 methyl 3-methyl-1-oxido-pyridin-1-ium-2-carboxylate 
• 59718-84-2 3-methyl-pyridine-2-carboxylic acid methyl ester 
• 878207-92-2 methyl 6-chloro-3-methyl-pyridine-2-carboxylate 
• 1201924-31-3 6-chloro-3-methyl-pyridine-2-carbonitrile 
• 159727-88-5 3-methyl-1-oxido-pyridin-1-ium-2-carbonitrile 
• 20970-75-6 2-cyano-3-methylpyridine 

Downstream Products

• 878207-92-2 methyl 6-chloro-3-methyl-pyridine-2-carboxylate 
• 1201924-34-6 methyl 3-(bromomethyl)-6-chloropicolinate 
• 1529760-72-2 methyl 4-[(6-chloro-3-methyl-pyridine-2-carbonyl)amino]-3,5-dimethyl-benzoate 
• 930303-55-2 2-chloro-1,7-naphthyridin-8(7H)-one 

Relevant articles and documents

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, we report a series of potent RIPK1 inhibitors, represented by compound 70. Compound 70 efficiently blocks necroptosis induced by TNFα in both human and mouse cells (EC50 = 17–30 nM). Biophysical assay demonstrates that compound 70 potently binds to RIPK1 (Kd = 9.2 nM), but not RIPK3 (Kd > 10,000 nM). Importantly, compound 70 exhibits greatly improved metabolic stability in human and rat liver microsomes compared to compound 6 (PK68), a RIPK1 inhibitor reported in our previous work. In addition, compound 70 displays high permeability in Caco-2 cells and excellent in vitro safety profiles in hERG and CYP assays. Moreover, pre-treatment of 70 significantly ameliorates hypothermia and lethal shock in SIRS mice model. Lastly, compound 70 possesses favorable pharmacokinetic parameters with moderate clearance and good oral bioavailability in SD rat. Taken together, our work supports 70 as a potent RIPK1 inhibitor and highlights its potential as a prototypical lead for further development in necroptosis-associated inflammatory disorders.

DIMETHYLBENZOIC ACID COMPOUNDS

The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor.

INHIBITORS OF JANUS KINASES

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.